Yesterday, the Foundation met with company representatives, industry experts and investors to explore how patient reach data can be used to help advance #globalhealthequity
Read more on our work with investors ➡️ https://t.co/9DAR1DydSe
#PRIinperson#AccesstoMedicine
Steffi Van Uytfanghe, Company Engagement Officer at the Access to Medicine Foundation discusses gaps in access to medical oxygen and how industry stakeholders are collaborating to solve them ➡️ https://t.co/GZZzbbXZg8
#MedicalOxygen#GlobalHealthEquity
Generic medicine manufacturers produce up to 80% of medicines by volume worldwide. As Africa’s #healthcare needs evolve, their role in access grows. But there is no single approach: strategies depend on scale, capabilities, reach & financing.
Learn more➡️ https://t.co/eqjCHjePHy
Across Africa, #HealthSystems face rising #NCDs alongside longstanding unmet needs. #CVD & #diabetes add pressure, while maternal mortality remains high.
Generic medicine manufacturers can help strengthen supply & expand #Access2Meds.
Learn more➡️ https://t.co/eqjCHjePHy
#Access2Meds depends on more than whether a product reaches the market. Across Africa, reliance on imported medicines can disrupt supply. Even when medicines are available, other barriers can stand in the way. What is needed to close this gap?➡️https://t.co/eqjCHjePHy
In a @devex op-ed, our CEO @JayasreeKIyer examines what shrinking foreign aid means for Africa’s #HealthSystems. She argues for long-term resilience over short-term fixes & asks whether this moment can build a more self-sustaining future. Read more➡️https://t.co/fX3klguG42
What began in 2018 with research on how generic medicine manufacturers respond to #AMR has grown into a dedicated programme looking more broadly at their role in #Access2Meds.
Our new report, coming soon, will add to this growing body of work.
Learn more➡️https://t.co/GOPCD0CNA5
Generic & biosimilar medicine manufacturers produce an estimated 80% of medicines by volume worldwide. Yet essential medicines remain out of reach for millions. We analyse company action & engage manufacturers on where stronger efforts can expand access➡️https://t.co/GOPCD0CNA5
Africa manufactures only a fraction of the #vaccines it needs. But momentum is building. #Tech transfers can help turn that momentum into stronger local manufacturing capacity. Read more in our latest review➡️https://t.co/DIyBpA3oMg #Access2Meds#HealthEquity#GlobalHealth
Planning for access early can help new medicines reach people faster. MSD’s agreements with seven manufacturers for alimatravir could help strengthen supply and affordability. However, some key Latin American countries are not included. Read more➡️https://t.co/Dq7C6ptHuq
In her latest op-ed for @IndiaHealthFund, our CEO, @JayasreeKIyer, explores why investing in maternal & child health is both a moral imperative & a trillion-dollar economic opportunity, & why innovation must reach those who need it most. Read more➡️https://t.co/aFpqISt89f
On #WorldSickleCellDay, we highlight the need to expand access to diagnosis, treatment & care for people living w/ #SickleCell disease. At the Foundation, we engage w/ 10+ key companies across the ecosystem to understand barriers & support wider access.
🔗https://t.co/vfOqbSi42z
What does innovation mean if it doesn’t reach the people who need it? Anathi Nqothole shares how gaining access to a new HIV prevention medication changed her life. Join us on the mission to make #GlobalHealth equity a reality➡️https://t.co/IA1wWhspgY #InvestinAccess#Access2Meds
For years, supplying medicines in #LMICs was treated as an afterthought. Today, 17 #pharma companies are planning for access while medicines are still in development, helping lifesaving products reach people faster.
#InvestinAccess➡️https://t.co/IA1wWhrRrq
#Access2Meds